CTRP Terminology
CTRP Agent Terminology
NCIt Antineoplastic Agent Terminology
GDC Terminology
GDC Therapeutic Agent Terminology
NCI Drug Dictionary Terminology
GDC Value Terminology
Pharmacologic Substance
Antiparasitic Agent
Enzyme Inhibitor
Sodium Stibogluconate
12001-86-4
16037-91-5
475763
475763
475763
A substance being studied in the treatment of certain solid tumors, lymphoma, and myeloma. Sodium stibogluconate may block enzymes needed for cancer growth. It is a type of pentavalent antimonial.
Antimony Sodium Gluconate
C0030895
C12H18O17Sb2.2Na
C61083
CHEBI:28148
CTRP
FDA
GDC
Lenocta
Myostibin
Organic Chemical
Pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phosphorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis.
Pentostam
Pharmacologic Substance
SODIUM STIBOGLUCONATE ANHYDROUS
SSG
Sodium Stibogluconate
Sodium Stibogluconate
Sodium Stibogluconate
Sodium Stibogluconate
Sodium_Stibogluconate
Solustibosan
Solustin
V083S0159D
VQD001
sodium stibogluconate
FDA Established Names and Unique Ingredient Identifier Codes Terminology